| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | T M MacDonald | |
| A D McMahon | |||
| P2860 | cites work | Why we need observational studies to evaluate the effectiveness of health care | Q24655465 |
| Falsificationism and clinical trials. | Q30365070 | ||
| Record-linkage for pharmacovigilance in Scotland | Q33540453 | ||
| Methods in health services research. Interpreting the evidence: choosing between randomised and non-randomised studies | Q33699720 | ||
| Generalisation and extrapolation | Q33791406 | ||
| Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. The DARTS/MEMO Collaboration. Diabetes Audit and Research in Tayside Scotland. Medicines Monitoring Unit. | Q34743735 | ||
| Use of the UK General Practice Research Database for pharmacoepidemiology | Q35802395 | ||
| Guide to interpreting and evaluating the pharmacoepidemiologic literature | Q35878958 | ||
| The clinical trial as a paradigm for epidemiologic research | Q38652659 | ||
| A study in contrasts: eligibility criteria in a twenty-year sample of NSABP and POG clinical trials. National Surgical Adjuvant Breast and Bowel Program. Pediatric Oncology Group | Q39227159 | ||
| Epidemiologic methods in clinical trials | Q40763541 | ||
| Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials | Q41187186 | ||
| Double standards, scientific methods, and epidemiologic research | Q41626790 | ||
| Evidence in medicine: invited commentary | Q41704028 | ||
| Why the Safety Assessment of Marketed Medicines (SAMM) guidelines are needed | Q41781852 | ||
| Pharmacovigilance in the 1990s | Q41879997 | ||
| Clinical trials and epidemiology | Q43489952 | ||
| Problems with using observational databases to compare treatments | Q43641799 | ||
| Striving to deconfound the fundamentals of epidemiologic study design | Q44167094 | ||
| The "case-control" study: valid selection of subjects | Q44277220 | ||
| Is the randomized controlled trial the real paradigm in epidemiology? | Q44542404 | ||
| Controls who experienced hypothetical causal intermediates should not be excluded from case-control studies | Q44949107 | ||
| Principles of nonexperimental assessment of excess risk, with special reference to adverse drug reactions | Q45282306 | ||
| Taxonomic axes of epidemiologic study designs: a refutationist perspective. | Q50702622 | ||
| A cohort study (with re-sampled comparator groups) to measure the association between new NSAID prescribing and upper gastrointestinal hemorrhage and perforation. | Q50959758 | ||
| Avoidance of bias in cohort studies. | Q52671445 | ||
| The need for randomization in the study of intended effects. | Q52707027 | ||
| Selection of controls in case-control studies. I. Principles | Q52861899 | ||
| Developing improved observational methods for evaluating therapeutic effectiveness. | Q52864032 | ||
| Selection of patients for randomized controlled trials: implications of wide or narrow eligibility criteria. | Q52866580 | ||
| Principles of epidemiological research on adverse and beneficial drug effects. | Q52907014 | ||
| THE DESIGN AND LOGIC OF A MONITOR OF DRUG USE. | Q53037618 | ||
| Behavior of the exposure odds ratio in a case-control study when the hazard function is not constant over time. | Q53412475 | ||
| Presentation: Epidemiology and public health: is a new paradigm needed or a new ethic? | Q53569297 | ||
| Experiment and observation. | Q53656454 | ||
| Clinical biostatistics. XX. The epidemiologic trohoc, the ablative risk ratio, and "retrospective" research. | Q54315521 | ||
| Case-control studies in the evaluation of drug-induced illness | Q67260512 | ||
| A collection of 56 topics with contradictory results in case-control research | Q68115062 | ||
| Classification schemes for epidemiologic research designs | Q68508152 | ||
| A method of pharmacoepidemiologic analysis that uses computerized Medicaid | Q68625795 | ||
| Cohorts versus dynamic populations: a dissenting view | Q69549555 | ||
| Subject selection in hospital-based case-control studies | Q69753515 | ||
| RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2 | Q69755626 | ||
| Post-marketing studies of drug efficacy: why? | Q70067466 | ||
| Tying clinical research to patient care by use of an observational database | Q70414526 | ||
| Post-marketing studies of drug efficacy: how? | Q70636123 | ||
| Postmarketing studies of drug efficacy: when must they be randomized? | Q71761952 | ||
| The evolution of clinical practice and time trends in drug effects | Q72169788 | ||
| Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research | Q72169848 | ||
| Drug exposure risk windows and unexposed comparator groups for cohort studies in pharmacoepidemiology | Q79899683 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | epidemiology | Q133805 |
| P304 | page(s) | 419-425 | |
| P577 | publication date | 2000-11-01 | |
| P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
| P1476 | title | Design issues for drug epidemiology | |
| P478 | volume | 50 |
| Q40097745 | Age and Sex Disparities in Discharge Statin Prescribing in the Stroke Belt: Evidence From the Reasons for Geographic and Racial Differences in Stroke Study |
| Q34427860 | An introduction to the fundamentals of cohort and case-control studies |
| Q35663453 | Assessing the impact of prescribed medicines on health outcomes |
| Q47604851 | Association of Antidepressant Medications With Incident Type 2 Diabetes Among Medicaid-Insured Youths. |
| Q28166985 | Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity |
| Q41581523 | Development and validation of a multivariate predictive model for rheumatoid arthritis mortality using a machine learning approach |
| Q51922725 | Development of a registry for monitoring psychotropic drug prescriptions: aims, methods and implications for ordinary practice and research. |
| Q48507669 | Disease Remission in Children and Adolescents with Intermediate Uveitis: A Survival Analysis. |
| Q37275612 | Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable |
| Q37162710 | Inappropriate drug use and risk of transition to nursing homes among community-dwelling older adults |
| Q33811280 | Inhaled tobramycin effectively reduces FEV1 decline in cystic fibrosis. An instrumental variables analysis |
| Q37282191 | Observational research--opportunities and limitations |
| Q49822791 | Primary non-adherence and the new-user design |
| Q28385784 | Proton pump inhibitors and risk of periampullary cancers--A nested case-control study |
| Q93033845 | Re-evaluating Safety and Effectiveness of Dabigatran Versus Warfarin in a Nationwide Data Environment: A Prevalent New-User Design Study |
| Q37541489 | Risk factors for renal failure in pediatric patients with acute myeloid leukemia: a retrospective cohort study |
| Q34462037 | Risk of fracture and the concomitant use of bisphosphonates with osteoporosis-inducing medications |
| Q40638787 | Study control, violators, inclusion criteria and defining explanatory and pragmatic trials |
| Q36653410 | The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application |
| Q38048231 | The incident user design in comparative effectiveness research. |
Search more.